Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
Abstract Background The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an immunomodulatory drug that has shown promising properties and activity in a variety of hematological malignancies. This study evaluated the ef...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer
2024-04-01
|
| Col·lecció: | Discover Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1007/s12672-024-00965-7 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|